RxDoctor Payments Data

Heather Birmingham, PA

Physician Assistant · Alpena, MINPI 1457825549

Payments from drug & device makers

$3,301in general payments, 2019–2025

Across 166 payments — averaging $19.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$832
  • AbbVie$533
  • E.r. Squibb & Sons, L.L.C.$435
  • Regeneron Healthcare Solutions, Inc.$302
  • Sanofi$267
  • Amgen$222
  • plus $711 from 13 others

What the payments were for

  • Food & beverage$2,92389%
  • Education$37811%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,301 in reported general payments places this provider in the 90th percentile of 5,453 physician assistant providers in Michigan.

See all physician assistant providers in Michigan

Medicare billing

Part B allowed, 2024
$228,116
Medicare patients
1,085
Services billed
4,385

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa27$530,850
Cosentyx Unoready PenSecukinumab45$429,865
Cosentyx Sensoready (2 Pens)Secukinumab25$198,666
SotyktuDeucravacitinib25$170,208
Humira(Cf) PenAdalimumab13$151,413
Dupixent PenDupilumab41$150,006
OtezlaApremilast32$149,741
Dupixent SyringeDupilumab26$98,873
Clobetasol Propionate240$7,654
Fluorouracil99$5,881
Ketoconazole262$5,101
Acitretin12$4,475
Triamcinolone Acetonide257$2,876
Ivermectin13$2,807
Metronidazole61$2,761

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
E.r. Squibb & Sons, L.L.C.Sotyktu$435$170,20825 claims
AmgenOtezla$222$149,74132 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 5,453 physician assistant providers in Michigan.

Other physician assistant in Alpena

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →